Skip to main content
. Author manuscript; available in PMC: 2011 Jun 3.
Published in final edited form as: Lancet Oncol. 2010 Sep 17;11(10):962–972. doi: 10.1016/S1470-2045(10)70203-5

Table 3.

Sites of disease progression triggering discontinuation of pazopanib

Primary sites of progression Clinical deterioration
Target only Target and non-target New and non-target
Partial response 3 1 8 0
Stable disease 3 0 3 1
Progression 1 0 6 1
Total 7 1 17 2